In this study, ixekizumab was better than placebo in improving self-reported functioning and health at weeks 16 and 52 in nonradiographic axial spondyloarthritis (SpA) patients.

• In this randomized, controlled trial (COAST-X), patients with nonradiographic axial SpA were randomly assigned 1:1:1 to receive 80 mg of ixekizumab subcutaneously every 4 weeks or 2 weeks or placebo for 52 weeks.

• Relative to placebo, ixekizumab conferred improvement of SF-36 (Short Form 36) physical component summary scores; the greatest improvements were evident in the domains of physical functioning, role-physical, and bodily pain at weeks 16 and 52.

• At weeks 16 and 52, ≥3 improvements based on the Assessment of Spondyloarthritis International Society (ASAS) health index occurred in a higher proportion of patients receiving ixekizumab therapy every 2 weeks.

• At weeks 16 and 52, improvements in “good health status” on the ASAS health index (ASAS score of ≤5) were evident in significantly more patients taking ixekizumab every 4 weeks.

• Ixekizumab users exhibited improvements on the EQ-5D-5L (European Quality of Life-5 Dimensions-5 Level) than those treated with placebo at week 16, which remained consistent at week 52.

• No clinical meaningful differences in responses were identified depending on the ixekizumab dosing regimen for patients who took ixekizumab therapy every 2 weeks or every 4 weeks.